Fig A: This graph shows minimal difference between overall survival rates for people with osteosarcoma when treated with MAP chemotherapy (methotrexate, doxorubin and cisplatin) versus receiving MAP plus interferon therapy.


Featured Research

Interferon Shows No Benefit in EURAMOS-1 Trial

Adding pegylated interferon to post-surgery maintenance therapy for people with osteosarcoma showed no clear benefit beyond existing standard chemotherapy, according to recent findings from the ongoing EURAMOS-1 clinical trial.

Read More

Division Summary

Research and Training Details

Joint Appointment Faculty3
Research Fellows and Post Docs4
Research Graduate Students7
Total Annual Grant Award Dollars$2,566,350
Total Annual Industry Award Dollars$2,587,017
Total Publications58

Clinical Activities and Training

Staff Physicians8
Clinical Fellows3
Inpatient Encounters11,508
Outpatient Encounters17,393